A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

J. Mascarenhas, H. Kosiorek, J. Prchal, A. Yacoub, D. Berenzon, M. R. Baer, E. Ritchie, R. T. Silver, C. Kessler, E. Winton, M. C. Finazzi, A. Rambaldi, A. M. Vannucchi, D. Leibowitz, D. Rondelli, M. O. Arcasoy, R. Catchatourian, J. Vadakara, V. Rosti, E. HexnerM. Kremyanskaya, L. Sandy, J. Tripodi, V. Najfeld, N. Farnoud, M. E. Salama, R. S. Weinberg, R. Rampal, J. D. Goldberg, R. Mesa, A. C. Dueck, R. Hoffman

Research output: Contribution to journalLetter

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)2974-2978
Number of pages5
JournalLeukemia
Volume33
Issue number12
DOIs
StatePublished - Dec 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mascarenhas, J., Kosiorek, H., Prchal, J., Yacoub, A., Berenzon, D., Baer, M. R., Ritchie, E., Silver, R. T., Kessler, C., Winton, E., Finazzi, M. C., Rambaldi, A., Vannucchi, A. M., Leibowitz, D., Rondelli, D., Arcasoy, M. O., Catchatourian, R., Vadakara, J., Rosti, V., ... Hoffman, R. (2019). A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia, 33(12), 2974-2978. https://doi.org/10.1038/s41375-019-0524-7